World News

Thailand Detects First Case of Drug-Resistant Omicron BQ.1 Subvariant

Distressed Patriotic Flag Unisex T-Shirt - Celebrate Comfort and Country $11.29 USD Get it here>>


Thailand has detected its first case of the new Omicron BQ.1 subvariant, which experts believe could be highly contagious and resistant to the antibody medications used to protect against COVID-19.

The Center for Medical Genomics at Ramathibodi hospital issued a warning on Oct. 18 about BQ.1 and BQ.1.1, both of which are the descendants of the Omicron BA.5 subvariant.

One case of BQ.1 had been detected in Thailand based on the Global Initiative on Sharing Avian Influenza Data (GISAID)—an international genomic database for influenza viruses—the center said, without elaborating on the case.

The center cited an update from the U.S. Centers for Disease Control and Prevention indicating that BQ.1 and BQ.1.1 accounted for more than 11 percent of the current infections in the United States.

India also reported one case of BQ.1 in Pune, Maharashtra, on Tuesday.

The Center for Medical Genomics claimed that BQ.1 spreads 15 percent quicker than BA.5.2 and 14 percent faster than BA.2, and that it can potentially become a dominant strain by the end of the year or early 2023.

Both BA.2 and BA.5.2 are subvariants of Omicron, a SARS-CoV-2 strain.

However, the center stated that no clinical data suggests that BQ.1 and BQ.1.1 can cause severe infections or more deaths than previous subvariants.

BQ.1 and BQ.1.1 Have ‘Troublesome Doubling Time’

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said the two sublineages have “qualities or characteristics that could evade some of the interventions we have.”

“When you get variants like that, you look at what their rate of increase is as a relative proportion of the variants, and this has a pretty troublesome doubling time,” he said in an interview with CBS News on Oct. 14.

Fauci said the BQ.1 and BQ.1.1 are potentially resistant to antibody drugs like Evusheld and have a higher transmission rate.

“That’s the reason why people are concerned about BQ.1.1, for the double reason of its doubling time and the fact that it seems to elude important monoclonal antibodies,” he explained.

A group of Chinese scientists published a study on Oct. 4, claiming that BQ.1.1 is one of the “most antibody-evasive strains tested” and is “far exceeding” that of Omicron BA.5 and approaching the coronavirus SARS-CoV-1 level.

The study was published on the biology preprint server bioRxiv but has not yet been peer-reviewed. It stated that BQ.1.1 exhibited strong resistance to antibody medications like Evusheld and Bebtelovimab.

Aldgra Fredly

Follow

Aldgra Fredly is a freelance writer based in Malaysia, covering Asia Pacific news for The Epoch Times.



Source link

TruthUSA

I'm TruthUSA, the author behind TruthUSA News Hub located at https://truthusa.us/. With our One Story at a Time," my aim is to provide you with unbiased and comprehensive news coverage. I dive deep into the latest happenings in the US and global events, and bring you objective stories sourced from reputable sources. My goal is to keep you informed and enlightened, ensuring you have access to the truth. Stay tuned to TruthUSA News Hub to discover the reality behind the headlines and gain a well-rounded perspective on the world.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.